346 related articles for article (PubMed ID: 33168408)
1. The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice.
Gao RF; Li X; Xiang HY; Yang H; Lv CY; Sun XL; Chen HZ; Gao Y; Yang JS; Luo W; Yang YQ; Tang YH
Int Immunopharmacol; 2021 Jan; 90():107133. PubMed ID: 33168408
[TBL] [Abstract][Full Text] [Related]
2. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
3. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.
van Hout GP; Bosch L; Ellenbroek GH; de Haan JJ; van Solinge WW; Cooper MA; Arslan F; de Jager SC; Robertson AA; Pasterkamp G; Hoefer IE
Eur Heart J; 2017 Mar; 38(11):828-836. PubMed ID: 27432019
[TBL] [Abstract][Full Text] [Related]
4. Bufalin reduces myocardial infarction-induced myocardial fibrosis and improves cardiac function by inhibiting the NLRP3/IL-1β signalling pathway.
Wei X; Lv Y; Yang C; Gao R; Zou S; Xu Y
Clin Exp Pharmacol Physiol; 2023 Aug; 50(8):688-697. PubMed ID: 37243403
[TBL] [Abstract][Full Text] [Related]
5. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
[TBL] [Abstract][Full Text] [Related]
6. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
7. Celastrol relieves myocardial infarction-induced cardiac fibrosis by inhibiting NLRP3 inflammasomes in rats.
Fan J; Ren M; Chen W; Wang H; He Y
Int Immunopharmacol; 2023 Aug; 121():110511. PubMed ID: 37343368
[TBL] [Abstract][Full Text] [Related]
8. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis.
Zhang L; Jiang YH; Fan C; Zhang Q; Jiang YH; Li Y; Xue YT
Biomed Pharmacother; 2021 Nov; 143():112133. PubMed ID: 34474337
[TBL] [Abstract][Full Text] [Related]
9. Inflammation: Targeting the NLRP3 inflammasome after MI.
Lim GB
Nat Rev Cardiol; 2016 Sep; 13(9):506. PubMed ID: 27489192
[No Abstract] [Full Text] [Related]
10. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
13. Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation.
Zhao M; Zhang J; Xu Y; Liu J; Ye J; Wang Z; Ye D; Feng Y; Xu S; Pan W; Wang M; Wan J
Int Immunopharmacol; 2021 Oct; 99():108046. PubMed ID: 34435581
[TBL] [Abstract][Full Text] [Related]
14. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway.
Zhang J; Huang L; Shi X; Yang L; Hua F; Ma J; Zhu W; Liu X; Xuan R; Shen Y; Liu J; Lai X; Yu P
Aging (Albany NY); 2020 Nov; 12(23):24270-24287. PubMed ID: 33232283
[TBL] [Abstract][Full Text] [Related]
15. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
16. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
[TBL] [Abstract][Full Text] [Related]
17. Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome.
Sano S; Oshima K; Wang Y; MacLauchlan S; Katanasaka Y; Sano M; Zuriaga MA; Yoshiyama M; Goukassian D; Cooper MA; Fuster JJ; Walsh K
J Am Coll Cardiol; 2018 Feb; 71(8):875-886. PubMed ID: 29471939
[TBL] [Abstract][Full Text] [Related]
18. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
[TBL] [Abstract][Full Text] [Related]
19. P2X
Yin J; Wang Y; Hu H; Li X; Xue M; Cheng W; Wang Y; Li X; Yang N; Shi Y; Yan S
J Cell Mol Med; 2017 Nov; 21(11):2695-2710. PubMed ID: 28470940
[TBL] [Abstract][Full Text] [Related]
20. Geranylgeranyl diphosphate synthase 1 knockdown suppresses NLRP3 inflammasome activity via promoting autophagy in sepsis-induced acute lung injury.
Li D; Li C; Wang T; Zhang C; Zhu Z; Zhang G; Fang B
Int Immunopharmacol; 2021 Nov; 100():108106. PubMed ID: 34530204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
